WallStSmart

Everpure, Inc. (P)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 1103% more annual revenue ($47.35B vs $3.94B). SNY leads profitability with a 16.0% profit margin vs 5.8%. P appears more attractively valued with a PEG of 1.53. P earns a higher WallStSmart Score of 57/100 (C).

P

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 3.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.16

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 4.7Quality: 6.3
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for P.

SNYUndervalued (+5.5%)

Margin of Safety

+5.5%

Fair Value

$49.78

Current Price

$44.38

$5.40 discount

UndervaluedFair: $49.78Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

P3 strengths · Avg: 9.0/10
EPS GrowthGrowth
139.7%10/10

Earnings expanding 139.7% YoY

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
20.4%8/10

Revenue surging 20.4% year-over-year

SNY5 strengths · Avg: 8.8/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Market CapQuality
$104.85B9/10

Large-cap with strong market position

Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

P4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Price/BookValuation
16.5x4/10

Trading at 16.5x book value

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SNY2 concerns · Avg: 2.0/10
PEG RatioValuation
3.812/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : P

The strongest argument for P centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : P

The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 109.6x leaves little room for execution misses.

Bear Case : SNY

The primary concerns for SNY are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

P profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

P carries more volatility with a beta of 1.45 — expect wider price swings.

P is growing revenue faster at 20.4% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

P scores higher overall (57/100 vs 51/100) and 20.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Everpure, Inc.

TECHNOLOGY · COMPUTER HARDWARE · USA

Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?